ABVX earnings

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical remission in participants with and without prior inadequate response to up to 4+ lines of advanced therapies including JAK inhibitors in the pooled ABTECT 1 & 2 Trials (w/AT-IR pbo adjusted D 10%, p=0.0009†; w/o AT-IR pbo adjusted D 22%, p<0.0001†)50mg obefazimod demonstrated clinically me

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8; met primary and all key secondary endpoints in both ABTECT 1 and ABTECT 2ABTECT trials enrolled refractory patient population with 47% of participants having prior inadequate response to advanced therapy, among whom 21% had prior inadequate response to JAK inhibitor therapyObefazimod treatment was well tolerated with no new safety signals identified for both the 25mg and 50mg doses Abivax to present a second late-breaking abstract on October 6. Management to host a conferen

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today that following the annual review of the Euronext Paris indices on September 11, 2025, the Scientific Council of the Indices has decided to admit Abivax to the CAC Mid 60 and SBF 120 indices. This decision will take effect on Friday, September 19, 2025, after market close. The CAC

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis   50 mg once-daily dose of obefazimod led to a compelling pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8 in the ABTECT-1 (Study 105) and ABTECT-2 (Study 106) trials. Individually, the 50 mg dose demonstrated a placebo-adjusted remission rate of 19.3% (p<0.0001) in ABTECT-1 and a placebo-adjusted remission rate of 13.4% (p=0.0001) in ABTECT-2.50 mg once-daily dose of obefazimod met all key secondary endpoints demonstrating highly statistically significant and clinica